HEB Hemispherx BioPharma Inc.

0.19
-0.01  -3%
Previous Close 0.2
Open 0.19
Price To Book 1.46
Market Cap 9122286
Shares 48,189,570
Volume 101,782
Short Ratio 1.48
Av. Daily Volume 271,095

SEC filingsSee all SEC filings

  1. 8-K - Current report 181228933
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181184649
  3. 8-K - Current report 181131603
  4. 8-K - Current report 181114577
  5. 8-K - Current report 181106764

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL February 4, 2013.
Ampligen
CFS

Latest News

  1. Hemispherx Biopharma Issues Letter to Stockholders
  2. Report: Developing Opportunities within Eaton Vance, IDT, Hemispherx BioPharma, Edgewell Personal Care, Rockwell Medical, and Avadel Pharmaceuticals — Future Expectations, Projections Moving into 2018
  3. Hemispherx Reports 2018 Third Quarter and First Nine Months Financial Results
  4. Hemispherx’s Presentation at the Dawson James Securities 4th Annual Small Cap Growth Conference to Be Livestreamed
  5. Hemispherx to Present at the Dawson James Securities 4th Annual Small Cap Growth Conference
  6. Hemispherx Outlines Ampligen Combination Therapy Clinical Study Strategy for the Treatment of Multiple Cancers in Letter to Stockholders
  7. Detailed Research: Economic Perspectives on Control4, REGENXBIO, Ferro, Kadmon, Hemispherx BioPharma, and Murphy Oil — What Drives Growth in Today's Competitive Landscape
  8. Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center to Study Ampligen in Combination with Checkpoint Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma
  9. Hemispherx to Distribute Second Lot of Ampligen® for use in Multiple Indications in Argentina, the United States and Europe
  10. Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks
  11. Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space

SEC Filings

  1. 8-K - Current report 181228933
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181184649
  3. 8-K - Current report 181131603
  4. 8-K - Current report 181114577
  5. 8-K - Current report 181106764
  6. S-8 - Securities to be offered to employees in employee benefit plans 181088998
  7. 8-K - Current report 181069027
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181018620
  9. EFFECT - Notice of Effectiveness 18993370
  10. EFFECT - Notice of Effectiveness 18993364